DELFI Diagnostics
Genomics & Genetic Testing · Diagnostic Tests & IVD
$331.6Mtotal raised · 5 rounds on record
5open roles
$153kmedian advertised pay
$225Mlatest round · Venture round · Jun 2022 · 4 yr ago
Overview
FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI Diagnostics.
Funding and backers
Total raised
$331.6M
5 rounds on record
Latest round
$225M
Venture round · Jun 2022 · 4 yr ago
Team
120
US Form 5500 (plan participants) · Dec 2025 · -17% in a year
Hiring now
6
+4 posted in 30 days
Backers
4
Foresite Capital, Illumina Ventures
The money's age
Long since its last round
52 months since the last round · and hiring
Momentum
27/100
hiring for its size
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 27
Board appointment DELFI Diagnostics Appoints Charles Newton to Board of Directors · PRNewswire
Dec 1, 2025
Took on debt financing $34.3M · SEC Form D
Oct 29, 2024
New executive DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening · PRNewswire
Aug 26, 2024
New executive DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer · PRNewswire
Jun 11, 2024
Partnership Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities · PRNewswire
Oct 10, 2023
Launched DELFI Diagnostics introduces FirstLook Lung blood test · Medical Device Network
Jun 10, 2022
Raised a round Venture round $225M · SEC Form D
Jan 12, 2021
Raised a round Venture round $101.1M · SEC Form D
Aug 12, 2019
Raised a round Venture round $5.5M · SEC Form D
2019
Founded
Jun 18, 2018
Raised a round Venture round $15k · SEC Form D
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Dec 2025 | $34.3M | — | SEC Form D |
| Venture round | Jun 2022 | $225M | — | SEC Form D |
| Venture round | Jan 2021 | $101.1M | — | SEC Form D |
| Venture round | Aug 2019 | $5.5M | — | SEC Form D |
| Venture round | Jun 2018 | $15k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Delfi Diagnostics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Nicholas DracopoliExecutive OfficerSEC Form D
Victor VelculescuDirectorSEC Form D
William StevensExecutive OfficerSEC Form D
Peter BachExecutive OfficerSEC Form D
Jennifer BuechelExecutive OfficerSEC Form D
Douglas SchenkelExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Precede Biosciences is a precision diagnostics and data company redefining what can be learned from a simple blood draw.
Pearl Diagnostics is changing the way clinicians diagnose lung infections. Our in vitro diagnostics identify circulating microbial…
Truvian is disrupting the blood diagnostics industry by developing an easy-to-use, automated benchtop blood testing analyzer. We’re…
SpotitEarly offers a new approach for cancer pre-screening, with a single at-home test for multiple cancer types, all based on one breath…
Human-grade cancer care for dogs. Origin combines cancer detection with a genomic health baseline. OncoTrack follows treatment response and…
Craif is a Tokyo biotechnology company founded in 2018 that detects cancer risk from urine samples. Its technology analyses microRNA using…
Jobs
$130k – $170k per year · Hybrid · Full-Time · 5+ years exp · Master's Degree · Palo Alto
Python
Statistical Process Control
Life Sciences
Next-Generation Sequencing
Design of Experiments
MedTech
Design Controls
Apply
$104k – $126k per year · In office · Contractor · 3+ years exp · Master's Degree · Palo Alto
Python
Next-Generation Sequencing
GLP
MedTech
Design Controls
Apply
$128k – $150k per year · In office · Contractor · 2+ years exp · Bachelor's Degree · Palo Alto
Next-Generation Sequencing
Apply
$110k – $130k per year · In office · Contractor · 2+ years exp · Bachelor's Degree · Palo Alto
Next-Generation Sequencing
Apply
$130k – $155k per year · In office · Full-Time · 5+ years exp · Bachelor's Degree · Palo Alto
Next-Generation Sequencing
Design of Experiments
MedTech
ISO 13485
ISO 14971
21 CFR Part 820
IVDR
Design Controls
Verification & Validation
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$153k
Typical range
$126k – $190k
Open positions
6
6
Jobs
Junior
33.3%
Senior
50%
Staff
16.7%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 2 | $140k | $130k – $150k |
| Senior | 3 | $155k | $126k – $170k |
| Staff | 1 | $190k | $190k |
Highest paying role
Facilities Manager (Contract)
$190k
Normalized to USD per year
All salaries at DELFI Diagnostics
By role, level and city, against the market · 6 jobs with pay
Visa sponsorship
2
H-1B filings in 12 months
1
Green card filings
$169k
Median offered salary
Who they sponsor
Financial and investment analysts
1
Data scientists
1
In the register as Delfi Diagnostics, Inc., Baltimore, MD (+1 more)
Other sponsors in the same field
ARUP Laboratories 
Natera 
Veracyte 
Myriad Genetics
See 6 open roles Alert me
US Department of Labor · latest filing May 14, 2026 · Visa details by country
Growth
Hiring Momentum
79/100
Scaling fast
Open positions
6
3 opened / 3 closed in 30 days
Median time-to-fill
47 days
faster than 29% of the market
ATS activity
Every ~4 hours
11/07/2026
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Data Science
20%
Science & Research
20%
Field & Service
20% ▲
Finance
10% ▼
Operations
10% ▲
Industrial Engineering
10% ▼
Activity Timeline
Added GLP to stack
Oct 2026
Added Verification & Validation to stack
Oct 2026
Added Next-Generation Sequencing to stack
Oct 2026
Added IVDR to stack
Oct 2026
Added ISO 14971 to stack
Oct 2026
Added ISO 13485 to stack
Oct 2026
Added Design of Experiments to stack
Oct 2026
Added Design Controls to stack
Oct 2026
Added 21 CFR Part 820 to stack
Oct 2026
Added Machine Learning to stack
Sep 2026
Financials
Total raised
$365.9M
Latest round
Debt Financing
Funding rounds
5
People
Nicholas Dracopoli
Executive Officer
Victor Velculescu
Director
William Stevens
Executive Officer
Peter Bach
Executive Officer
Jennifer Buechel
Executive Officer
Douglas Schenkel
Executive Officer
Lee-Ann Smith-Freeman
Executive Officer
Susan Tousi
Executive Officer, Director
Amoolya Singh
Executive Officer
Greg Yap
Director
Elizabeth Homans
Director
Rishi Gupta
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at DELFI Diagnostics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
20
Postings analysed
8
Stack modernity
71/100
Languages
Python
C#
C++
Java
Frameworks & libraries
NumPy
Cloud & platforms
AWS
Sign in to see how your skills match this stack
Sign In
Full DELFI Diagnostics tech stack
20 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Illumina VenturesVia a fund
Foresite CapitalVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Menlo VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Blood Test Boosts Lung Cancer Screening Participation
Clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with CT screening.
Read more
Report
DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the lung cancer bood test available in all 50 states.
Read more
Report
Delfi Diagnostics Gains NY State Approval for Blood-Based Lung Cancer LDT
Delfi's laboratory-developed lung cancer screening test is now available nationwide while the company continues to pursue FDA approval.
Read more
Report
DELFI Diagnostics Receives New York State Department of Health Clinical Laboratory Permit, Completing Authorization to Serve Health Systems Across All 50 States
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory...
Read more
Report
The New Blood Test That's Helping Doctors Screen For Lung Cancer Sooner
Learn how doctors at Hackensack Meridian Health are using a new lung cancer blood test to screen for the disease sooner and improve cancer outcomes.
Read more
Report
Delfi Diagnostics Gives 'First Look' at Clinical Utility of cfDNA Assay in Lung Cancer Screening
Access to the liquid biopsy nearly tripled lung cancer screening rates in a demonstration of the test's clinical utility.
Read more
Report
DELFI Diagnostics to Present First Clinical Utility Data for Blood-Based Lung Cancer Screening at ATS 2026 International Conference
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and...
Read more
Report
DELFI Diagnostics Appoints Charles Newton to Board of Directors
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative AI-powered blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer...
Read more
Report
Johns Hopkins Researchers Develop Fragmentomic Test for Pancreatic Cancer Treatment Response
The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.
Read more
Report
Could a blood test detect lung cancer?
Lung cancer accounts for 1 in 5 cancer-related deaths in the United States. While doctors say lung cancer is often treatable if caught early, millions of Americans who should be getting screened for the disease each year are not either due to lack of awar
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
1
Countries
1
Busiest office
Palo Alto
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Palo Alto
United States
HQ
For the latest press releases and media coverage, visit:
6 open roles 10 posted in 90 days 33% engineering 50-200 est. staff $154k Avg Salary
hires for Field & Service, Data Science, Operations
Page
United States
HQ
Company Information and Fact Page
1810 Embarcadero Road, Suite 100, Palo Alto, CA 94303
Medina
United States
Regional office
Other Applications
Medina, J.E., et al. "Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers." Cancer Discovery. 2024. DOI: